Ipca Laboratories announced its unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. Standalone Net Total Income grew 11% to Rs. 1,863.00 crores for the quarter, while Consolidated Net Total Income rose 7% to Rs. 2,412.69 crores. Standalone Net Profit after tax increased 13% to Rs. 303.45 crores, and Consolidated Net Profit saw a strong jump of 31% to Rs. 326.27 crores.
Financial Highlights for Q3 FY26
Ipca Laboratories Limited declared its unaudited financial results for the third quarter ended December 31, 2025, reporting robust growth across key metrics. The Board of Directors approved these results on February 13, 2026.
Standalone Performance (Q3 FY26 vs Q3 FY25)
- Standalone Net Total Income increased 11% to Rs. 1,863.00 crores.
- Standalone EBITDA margin improved to 26.09% from 24.25% in Q3 FY25.
- Indian formulations income grew 12% to Rs. 984.00 crores.
- Exports Income showed a growth of 13%, reaching Rs. 770.49 crores.
- Standalone Net Profit after tax (after exceptional items) rose 13% to Rs. 303.45 crores.
Consolidated Performance (Q3 FY26 vs Q3 FY25)
- Consolidated Net Total Income grew 7% to Rs. 2,412.69 crores.
- Consolidated EBITDA margin improved to 22.15% from 19.87% in Q3 FY25.
- Consolidated Net Profit after tax (after exceptional items) surged 31% to Rs. 326.27 crores.
Nine Months Ended (9M FY26) Performance Summary
Standalone Nine Months FY26
- Standalone Net Total Income grew 10% to Rs. 5,587.16 crores.
- Standalone EBITDA margin was 25.15%, up from 23.14% in FY25.
- Standalone Net Profit after tax increased 22% to Rs. 870.23 crores.
Consolidated Nine Months FY26
- Consolidated Net Total Income grew 9% to Rs. 7,338.56 crores.
- Consolidated EBITDA margin reached 20.79%, compared to 19.18% in FY25.
- Consolidated Net Profit after tax increased 26% to Rs. 842.05 crores.
Operational & Segment Review
Q3 FY26 Revenue Break-up (Consolidated)
Formulations revenue grew 14% to Rs. 1,518.96 crores, driven by a 12% increase in Domestic Formulations (Rs. 984.00 crores) and a 28% surge in Branded Exports (Rs. 204.87 crores). Total APIs revenue remained flat at Rs. 317.06 crores.
9M FY26 Revenue Break-up (Consolidated)
Total Formulations revenue increased 9% to Rs. 4,441.19 crores. Total APIs revenue saw growth of 14%, reaching Rs. 1,051.18 crores, primarily due to strong Exports growth of 26%.
Exceptional Items and Other Disclosures
Exceptional items for the quarter totaled an expense of Rs. 17.65 crores on the standalone basis, related to the net gain/loss on disposal of land and building. On the consolidated side, the exceptional item expense was also Rs. 17.65 crores, noting a provision for the European Commission Fine settled in October 2025.
The company further noted the acquisition of 100% equity interest in Unichem Laboratories Limited, Ireland, and the incorporation of a wholly-owned subsidiary in Germany during the nine-month period.
Source: BSE
